US OptionsDetailed Quotes
DDD250117C20000
- 0.01
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
0.01Open0.01Pre Close0 Volume1.91K Open Interest20.00Strike Price0.00Turnover383.05%IV490.27%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0146Delta0.0156Gamma339.00Leverage Ratio-0.0032Theta0.0000Rho4.96Eff Leverage0.0002Vega
3D Systems Stock Discussion
Sign in to post a comment
The market fell on Thursday after tech stocks hit all-time highs Wednesday, and inflation in the prices companies pay rose more than expected.
Overall, the market was falling after the Nasdaq hit a record over 20k Wednesday. Past 4:09 pm ET the $S&P 500 Index (.SPX.US)$ traded -0.54%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.53%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 0.66%.
MACRO
Thursday's macro in numbers showe...
Overall, the market was falling after the Nasdaq hit a record over 20k Wednesday. Past 4:09 pm ET the $S&P 500 Index (.SPX.US)$ traded -0.54%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.53%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 0.66%.
MACRO
Thursday's macro in numbers showe...
21
1
5
$3D Systems (DDD.US)$
3D Systems Expands Orthopedic Surgical Planning Portfolio Receiving FDA Clearance for Key Ankle Indications
3D Systems (NYSE:DDD) has received FDA 510(k) clearance for its TOTAL ANKLE Patient-Matched Guides, designed to work with Smith+Nephew's total ankle replacement solutions. This expansion of 3D Systems' orthopedic surgical planning portfolio leverages the company's VSP surgical planning workflows and advanced 3D printing technologies. The patient-specific guides ai...
3D Systems Expands Orthopedic Surgical Planning Portfolio Receiving FDA Clearance for Key Ankle Indications
3D Systems (NYSE:DDD) has received FDA 510(k) clearance for its TOTAL ANKLE Patient-Matched Guides, designed to work with Smith+Nephew's total ankle replacement solutions. This expansion of 3D Systems' orthopedic surgical planning portfolio leverages the company's VSP surgical planning workflows and advanced 3D printing technologies. The patient-specific guides ai...
1
Morning Movers
Gapping up
$TJX Companies (TJX.US)$ earnings beat by $0.04, and its revenue topped estimates. Shares rose by 3.5% in premarket trading.
$Target (TGT.US)$ stock soared 14.6% after the big box retailer raised its annual profit forecast and beat expectations for second-quarter comparable sales, attracting customers with low priced groceries and essentials.
$Toll Brothers (TOL.US)$ stock rose by 0.9% after the homebuildi...
Gapping up
$TJX Companies (TJX.US)$ earnings beat by $0.04, and its revenue topped estimates. Shares rose by 3.5% in premarket trading.
$Target (TGT.US)$ stock soared 14.6% after the big box retailer raised its annual profit forecast and beat expectations for second-quarter comparable sales, attracting customers with low priced groceries and essentials.
$Toll Brothers (TOL.US)$ stock rose by 0.9% after the homebuildi...
26
1
5
$3D Systems (DDD.US)$
NAMI Selects 3D Systems’ Metal & Polymer Additive Manufacturing Solutions to Power Streamlined Supply Chain for Saudi Electricity Company
3D Systems announced that NAMI has purchased their metal and polymer additive manufacturing technologies to enhance the supply chain of the Saudi Electricity Company (SEC).
Technologies include the DMP Factory 500, DMP Flex 350 Dual, and SLS 380. This will support SEC in producing spare parts locally, reducing production time, storage ...
NAMI Selects 3D Systems’ Metal & Polymer Additive Manufacturing Solutions to Power Streamlined Supply Chain for Saudi Electricity Company
3D Systems announced that NAMI has purchased their metal and polymer additive manufacturing technologies to enhance the supply chain of the Saudi Electricity Company (SEC).
Technologies include the DMP Factory 500, DMP Flex 350 Dual, and SLS 380. This will support SEC in producing spare parts locally, reducing production time, storage ...
1
$3D Systems (DDD.US)$ Near suport level, but it will ermain volatile till Q3. I am not seeing any sustained gain before Q3. Stock will range bound.
5
CEO Dr. Jeffrey Graves believes that the repurchase demonstrates the company's proactive approach to liability management and its commitment to maintaining a strong balance sheet. He also expresses confidence in the company's position to deliver on its long-term future.
1
CEO Dr. Jeffrey Graves asserts that streamlining commercial operations will bolster go-to-market strategies, cut costs, and improve the company's agility in responding to market shifts. He also stressed the need to maintain a strong focus on the distinct needs of Healthcare and Industrial customers.
No comment yet
103677010 : noted